KYAN Technologies: Difference between revisions

Line 1:

~~{{Draft}}~~

{{Infobox Startup

|logo=Kyan therapeutics logo.jpg

Line 10:

Line 9:

|headquarters=Singapore

}}

KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development.

KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development in oncology.

==Technology==

KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based ~~platofrm~~ to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types.

KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platform to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types.

The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>.

==Traction==

~~List notable customers or partnerships here~~. ~~Awards should not be listed here~~, ~~but under "Accolades" instead~~

KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Science Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.

==~~Accolades~~==

In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web |last=admin |date=2025-02-05 |title=KYAN Technologies announces collaboration with OncoCare Malaysia |url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>.

~~List awards received by~~ the startup ~~here~~.

In March 2025, KYAN Technologies entered a collaboration with Mayo Clinic Laboratories to validate and provide the startup's testing platform across the United States<ref>{{Cite web |last=admin |date=2025-03-13 |title=Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing |url=https://kyantechnologies.com/mayo-clinic-laboratories-and-kyan-technologies-enter-a-collaboration-to-expand-patients-access-to-cancer-testing/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>.

==Funding==

KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>.{{Startup/Funding history}}

KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>{{Startup/Funding history}}

~~== See also ==~~

* List any other pages directly relevant to {{PAGENAME}}

== References ==

@@ Line 1: / Line 1: @@
-{{Draft}}
 {{Infobox Startup
 |logo=Kyan therapeutics logo.jpg
@@ Line 10: / Line 9: @@
 |headquarters=Singapore
 }}
-KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development.
+KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development in oncology.
 ==Technology==
-KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types.
+KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platform to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types.
 The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>.
 ==Traction==
-List notable customers or partnerships here. Awards should not be listed here, but under "Accolades" instead
+KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Science Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.
-==Accolades==
+In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web |last=admin |date=2025-02-05 |title=KYAN Technologies announces collaboration with OncoCare Malaysia |url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>.
-List awards received by the startup here.
+In March 2025, KYAN Technologies entered a collaboration with Mayo Clinic Laboratories to validate and provide the startup's testing platform across the United States<ref>{{Cite web |last=admin |date=2025-03-13 |title=Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing |url=https://kyantechnologies.com/mayo-clinic-laboratories-and-kyan-technologies-enter-a-collaboration-to-expand-patients-access-to-cancer-testing/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>.
 ==Funding==
-KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>.{{Startup/Funding history}}
+KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>{{Startup/Funding history}}
-== See also ==
-* List any other pages directly relevant to {{PAGENAME}}
 == References ==
 {{Reflist}}